221 related articles for article (PubMed ID: 16509026)
1. Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure.
Gerhard T; Zineh I; Winterstein AG; Hartzema AG
Pharmacotherapy; 2006 Jan; 26(1):34-43. PubMed ID: 16509026
[TBL] [Abstract][Full Text] [Related]
2. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure.
de Lissovoy G; Stier DM; Ciesla G; Munger M; Burger AJ
Am J Cardiol; 2003 Sep; 92(5):631-3. PubMed ID: 12943895
[TBL] [Abstract][Full Text] [Related]
3. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
Arnold LM; Crouch MA; Carroll NV; Oinonen MJ
Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
[TBL] [Abstract][Full Text] [Related]
4. Dobutamine Therapy is Associated with Worse Clinical Outcomes Compared with Nesiritide Therapy for Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.
Wang XC; Zhu DM; Shan YX
Am J Cardiovasc Drugs; 2015 Dec; 15(6):429-37. PubMed ID: 26123415
[TBL] [Abstract][Full Text] [Related]
5. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure.
Silver MA; Horton DP; Ghali JK; Elkayam U
J Am Coll Cardiol; 2002 Mar; 39(5):798-803. PubMed ID: 11869844
[TBL] [Abstract][Full Text] [Related]
6. Increased cost effectiveness with nesiritide vs. milrinone or dobutamine in the treatment of acute decompensated heart failure.
Scroggins N; Edwards M; Delgado R
Congest Heart Fail; 2005; 11(6):311-4. PubMed ID: 16330906
[TBL] [Abstract][Full Text] [Related]
7. Risk of death with nesiritide.
Burger AJ
JAMA; 2005 Aug; 294(8):897; author reply 898. PubMed ID: 16118377
[No Abstract] [Full Text] [Related]
8. Nesiritide Therapy Is Associated With Better Clinical Outcomes Than Dobutamine Therapy in Heart Failure.
Kong LG; Wang CL; Zhao D; Wang B
Am J Ther; 2017; 24(2):e181-e188. PubMed ID: 26164026
[TBL] [Abstract][Full Text] [Related]
9. Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure.
Aronson D; Burger AJ
Am Heart J; 2004 Nov; 148(5):e16. PubMed ID: 15523294
[TBL] [Abstract][Full Text] [Related]
10. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study.
Burger AJ; Horton DP; LeJemtel T; Ghali JK; Torre G; Dennish G; Koren M; Dinerman J; Silver M; Cheng ML; Elkayam U;
Am Heart J; 2002 Dec; 144(6):1102-8. PubMed ID: 12486437
[TBL] [Abstract][Full Text] [Related]
11. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials.
Sackner-Bernstein JD; Kowalski M; Fox M; Aaronson K
JAMA; 2005 Apr; 293(15):1900-5. PubMed ID: 15840865
[TBL] [Abstract][Full Text] [Related]
12. The use of recombinant human B-type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure.
Strain WD
Int J Clin Pract; 2004 Nov; 58(11):1081-7. PubMed ID: 15605677
[TBL] [Abstract][Full Text] [Related]
13. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
[TBL] [Abstract][Full Text] [Related]
14. The ASCEND-HF trial: an acute study of clinical effectiveness of nesiritide and decompensated heart failure.
Dandamudi S; Chen HH
Expert Rev Cardiovasc Ther; 2012 May; 10(5):557-63. PubMed ID: 22651831
[TBL] [Abstract][Full Text] [Related]
15. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
de Lissovoy G; Fraeman K; Salon J; Chay Woodward T; Sterz R
J Med Econ; 2008; 11(3):415-29. PubMed ID: 19450096
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of patients hospitalized for acute decompensated heart failure: does nesiritide make a difference?
Carroll RJ; Mulla ZD; Hauck LD; Westbrook A
BMC Cardiovasc Disord; 2007 Nov; 7():37. PubMed ID: 18039381
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF).
Gheorghiade M; Gattis WA; Adams KF; Jaffe AS; O'Connor CM; ;
Am Heart J; 2003 Feb; 145(2 Suppl):S55-7. PubMed ID: 12594453
[No Abstract] [Full Text] [Related]
18. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy.
Burger AJ; Elkayam U; Neibaur MT; Haught H; Ghali J; Horton DP; Aronson D
Am J Cardiol; 2001 Jul; 88(1):35-9. PubMed ID: 11423055
[TBL] [Abstract][Full Text] [Related]
19. Nesiritide: a review of its use in acute decompensated heart failure.
Keating GM; Goa KL
Drugs; 2003; 63(1):47-70. PubMed ID: 12487622
[TBL] [Abstract][Full Text] [Related]
20. Intravenous nesiritide in acute heart failure.
Knox MA; Dancy T; Mook W; Pschirer JJ
Am J Ther; 2005; 12(3):233-7. PubMed ID: 15891267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
